AU2021332085B2 - Glucosidase inhibitors for the treatment and prevention of pulmonary infections - Google Patents

Glucosidase inhibitors for the treatment and prevention of pulmonary infections Download PDF

Info

Publication number
AU2021332085B2
AU2021332085B2 AU2021332085A AU2021332085A AU2021332085B2 AU 2021332085 B2 AU2021332085 B2 AU 2021332085B2 AU 2021332085 A AU2021332085 A AU 2021332085A AU 2021332085 A AU2021332085 A AU 2021332085A AU 2021332085 B2 AU2021332085 B2 AU 2021332085B2
Authority
AU
Australia
Prior art keywords
groups
optionally substituted
glucosidase inhibitor
subject
agis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021332085A
Other languages
English (en)
Other versions
AU2021332085A1 (en
Inventor
Sebastian Mario Marcuccio
David Alexander Vodden Morton
Simon Peter Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covirix Medical Pty Ltd
Original Assignee
Covirix Medical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903051A external-priority patent/AU2020903051A0/en
Application filed by Covirix Medical Pty Ltd filed Critical Covirix Medical Pty Ltd
Publication of AU2021332085A1 publication Critical patent/AU2021332085A1/en
Application granted granted Critical
Publication of AU2021332085B2 publication Critical patent/AU2021332085B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2021332085A 2020-08-26 2021-08-25 Glucosidase inhibitors for the treatment and prevention of pulmonary infections Active AU2021332085B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903051 2020-08-26
AU2020903051A AU2020903051A0 (en) 2020-08-26 Compounds, compositions and uses thereof
PCT/AU2021/050978 WO2022040741A1 (en) 2020-08-26 2021-08-25 Glucosidase inhibitors for the treatment and prevention of pulmonary infections

Publications (2)

Publication Number Publication Date
AU2021332085A1 AU2021332085A1 (en) 2022-05-19
AU2021332085B2 true AU2021332085B2 (en) 2022-12-08

Family

ID=80352192

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021332085A Active AU2021332085B2 (en) 2020-08-26 2021-08-25 Glucosidase inhibitors for the treatment and prevention of pulmonary infections

Country Status (6)

Country Link
US (1) US20240016786A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203954A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540259A (cg-RX-API-DMAC7.html)
CN (1) CN116419754A (cg-RX-API-DMAC7.html)
AU (1) AU2021332085B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022040741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100027464A1 (it) * 2021-10-26 2023-04-26 Univ Degli Studi Di Camerino Composizione comprendente iminozuccheri e/o anisodamina per il trattamento di infezioni virali
US12569473B2 (en) * 2022-07-05 2026-03-10 60 Degrees Pharmaceuticals, Inc. Methods to treat respiratory infection utilizing castanospermine analogs
CN119841765B (zh) * 2025-01-09 2025-10-10 中南大学 Dnj衍生物、药物组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
WO2017192599A1 (en) * 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors
WO2020185675A1 (en) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
WO2021168483A2 (en) * 2020-02-21 2021-08-26 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
AU2021202066A1 (en) * 2020-04-03 2021-10-21 Shenzhen Qianhai Nobel Laureates Technology Transfer Co., Ltd. Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2011095772A2 (en) * 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
US10980756B1 (en) * 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230270826A1 (en) * 2020-07-30 2023-08-31 Delta 4 Gmbh Antiviral use of liraglutide and gefitinib

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
WO2017192599A1 (en) * 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors
WO2020185675A1 (en) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
WO2021168483A2 (en) * 2020-02-21 2021-08-26 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
AU2021202066A1 (en) * 2020-04-03 2021-10-21 Shenzhen Qianhai Nobel Laureates Technology Transfer Co., Ltd. Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FUKUSHI, M. et al. Journal of Virology (2012) vol. 86, no. 21, pages 11745-11753 *
HOLWERDA, M. et al. "Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2" bioRxiv (2020) 1-25, Published 17 May 2020 *
HUSSAIN, S. et al. Journal of Antimicrobial Chemotherapy (2015) vol. 70, no. 1, pages 136-152 *
RAJASEKHARAN, S. et al. "Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2" bioRxiv (2020) 1-17, published 18 May 2020 *
TANAKA, Y. et al. Antiviral Research (2006) vol. 72, no. 1, pages 1-9 *
WARFIELD, K. L. et al. Journal of Medicinal Chemistry (2020) vol. 63, pages 4205-4214 (published 31 March 2020) *
WARFIELD, K. L. et al. Viruses (2016) vol. 8, no. 3, 71, 9 pages *
ZHAO, X. et al. Antimicrobial Agents and Chemotherapy (January 2015) vol. 59, no. 1, pages 206-216 *

Also Published As

Publication number Publication date
WO2022040741A1 (en) 2022-03-03
AU2021332085A1 (en) 2022-05-19
US20240016786A1 (en) 2024-01-18
CN116419754A (zh) 2023-07-11
JP2023540259A (ja) 2023-09-22
EP4203954A4 (en) 2025-01-01
EP4203954A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US12396986B2 (en) Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist
JP2024028720A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP6021117B2 (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
JP2020073494A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20240016786A1 (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
JP2014525471A (ja) 咳および咳発作の治療
TW200938232A (en) Novel dosage and formulation
KR20150018526A (ko) 아베디테롤의 신규한 투약 형태 및 제형
JP2023171770A (ja) クロファジミンの吸入可能な組成物およびその使用方法
CN117615765A (zh) 用ALK-5(TGFβR1)抑制剂治疗肺部疾病的方法
EP4151211A1 (en) Novel inhalant
TW201031409A (en) Novel methods
CN103561731A (zh) 包含芜地溴铵的干粉吸入器组合物
US20220378727A1 (en) Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
US20240041805A1 (en) Pharmaceutical compositions of niclosamide and a protein
HK40096612A (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
US20230270709A1 (en) Antiviral pharmaceutical composition for topical administration
TR201407010A2 (tr) Vilanterol formülasyonları.
US20240299379A1 (en) Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases
WO2005044233A1 (en) Formulations of n-oxide prodrugs of local anesthetics for the treatment of pulmonary inflammation associated with asthma, brochitis, and copd

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)